(Hypertension. 1998;31:237.)
© 1998 American Heart Association, Inc.
Scientific Contributions |
From the Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; and the Department of Biochemistry (J.R.F., K.M.R.), University of Texas, Southwestern Medical Center, Dallas, Texas.
Reprint requests to William B. Campbell, PhD, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
Neutrophils respond to ischemic injury by infiltrating the myocardium via the vascular wall. During this process, neutrophils are activated and release inflammatory mediators. Some of these mediators are metabolites of arachidonic acid. We have reported that neutrophils metabolize arachidonic acid to 20-HETE, a cytochrome P450 metabolite. We investigated the effects of 20-HETE on coronary vascular tone by examining 20-HETE-induced changes in isometric tension in bovine coronary artery rings precontracted with the thromboxane-mimetic, U46619. 20-HETE relaxed precontracted coronary rings in a concentration-dependent manner (EC50 of 3 x 10-7 mol/L). Pretreatment with indomethacin, a cyclooxygenase inhibitor, shifted the concentration-response curve to the right (EC50 of 1 x 10-6 mol/L); maximal relaxations were not affected. This suggested that 20-HETE-induced relaxations were, in part, dependent on the cyclooxygenase pathway. Relaxations to 20-HETE were not significantly changed in endothelium-denuded rings. To determine whether metabolism of 20-HETE to a vasoactive compound might explain the relaxations caused by 20-HETE, rings of coronary artery were incubated with [3H] 20-HETE. The incubation buffer was extracted and the [3H] products resolved on reverse-phase HPLC. Both denuded and intact arteries failed to metabolize [3H] 20-HETE. To investigate whether 20-HETE-induced relaxations were related to release of prostacyclin, we measured the release of 6-keto PGF1
, the stable metabolite of prostacyclin, from bovine coronary arteries. 20-HETE (1 x 10-6 mol/L) stimulated an increase in 6-keto PGF1
in intact vessels (908 ± 138 pg/mL versus 1402 ± 157 pg/mL, basal versus stimulated). Thus, 20-HETE-induced relaxations are due, in part, to the stimulation of the release of the dilatory prostanoid, prostacyclin.
Key Words: neutrophils cytochrome P450 coronary artery prostacyclin endothelium cyclooxygenase
This article has been cited by other articles:
![]() |
X. Fang, F. M. Faraci, T. L. Kaduce, S. Harmon, M. L. Modrick, S. Hu, S. A. Moore, J. R. Falck, N. L. Weintraub, and A. A. Spector 20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: role of cyclooxygenase Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2301 - H2307. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Granville and R. A. Gottlieb Having a heart attack? Avoid the "HETE"! Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H485 - H487. [Full Text] [PDF] |
||||
![]() |
G. J. Gross, J. R. Falck, E. R. Gross, M. Isbell, J. Moore, and K. Nithipatikom Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited Cardiovasc Res, October 1, 2005; 68(1): 18 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Huang, D. Sun, C. Yan, J. R. Falck, and G. Kaley Contribution of 20-HETE to Augmented Myogenic Constriction in Coronary Arteries of Endothelial NO Synthase Knockout Mice Hypertension, September 1, 2005; 46(3): 607 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. O. Oyekan Differential Effects of 20-Hydroxyeicosatetraenoic Acid on Intrarenal Blood Flow in the Rat J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1289 - 1295. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Kaduce, X. Fang, S. D. Harmon, C. L. Oltman, K. C. Dellsperger, L. M. Teesch, V. R. Gopal, J. R. Falck, W. B. Campbell, N. L. Weintraub, et al. 20-Hydroxyeicosatetraenoic Acid (20-HETE) Metabolism in Coronary Endothelial Cells J. Biol. Chem., January 23, 2004; 279(4): 2648 - 2656. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Roman P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function Physiol Rev, January 1, 2002; 82(1): 131 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yaghi, C. D. Webb, J. A. Scott, S. Mehta, J. R. Bend, and D. G. McCormack Cytochrome P450 Metabolites of Arachidonic Acid but Not Cyclooxygenase-2 Metabolites Contribute to the Pulmonary Vascular Hyporeactivity in Rats with Acute Pseudomonas Pneumonia J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 479 - 488. [Abstract] [Full Text] |
||||
![]() |
J. H. Capdevila, J. R. Falck, and R. C. Harris Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase J. Lipid Res., February 1, 2000; 41(2): 163 - 181. [Abstract] [Full Text] |
||||
![]() |
J. C. McGiff and J. Quilley 20-HETE and the kidney: resolution of old problems and new beginnings Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R607 - R623. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |